Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HH30134 in Advanced Solid Tumors
NCT04746612Phase 1Terminated
- Sponsor
- Haihe
- Start
- Apr 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of HH30134 in solid tumor, sponsored by Haihe. Primary endpoints: Dose limiting toxicities at 12 months and Maximum Tolerated Dose at 12 months. Started Apr 2021; status: terminated.
02
Drugs
HH30134
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04746612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746612.